Yuki Togashi

6.9k total citations · 2 hit papers
55 papers, 4.1k citations indexed

About

Yuki Togashi is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Yuki Togashi has authored 55 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 14 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Yuki Togashi's work include Lung Cancer Treatments and Mutations (13 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (10 papers) and Lung Cancer Research Studies (9 papers). Yuki Togashi is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (10 papers) and Lung Cancer Research Studies (9 papers). Yuki Togashi collaborates with scholars based in Japan, India and United States. Yuki Togashi's co-authors include Kengo Takeuchi, Hiroyuki Mano, Manabu Soda, Satoko Hatano, Yuichi Ishikawa, Young Lim Choi, Ken Nakagawa, Sakae Okumura, Yukitoshi Satoh and Kentaro Inamura and has published in prestigious journals such as Nature Medicine, PLoS ONE and Cancer.

In The Last Decade

Yuki Togashi

53 papers receiving 4.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RET, ROS1 and ALK fusions in lung cancer

2012 963 citations Kengo Takeuchi, Manabu Soda et al. Nature Medicine profile →
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

2009 557 citations Kengo Takeuchi, Young Lim Choi et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuki Togashi Japan	18	3.1k	2.3k	1.6k	1.1k	619	55	4.1k
Paula Marrano Canada	26	2.2k 0.7×	2.0k 0.8×	1.6k 1.1×	842 0.7×	237 0.4×	60	4.0k
Frédéric Chibon France	39	2.6k 0.8×	1.5k 0.6×	1.2k 0.8×	755 0.7×	873 1.4×	117	4.3k
Jeffrey Swensen United States	28	663 0.2×	1.3k 0.6×	1.2k 0.8×	754 0.7×	747 1.2×	87	3.1k
Akishi Ooi Japan	32	1.1k 0.4×	1.6k 0.7×	1.1k 0.7×	482 0.4×	339 0.5×	86	3.0k
Douglas I. Lin United States	26	916 0.3×	1.0k 0.4×	1.4k 0.9×	417 0.4×	263 0.4×	112	2.6k
Neeta Somaiah United States	30	1.7k 0.6×	1.4k 0.6×	793 0.5×	341 0.3×	331 0.5×	169	2.9k
Maija Tarkkanen Finland	28	1.5k 0.5×	889 0.4×	1.3k 0.8×	771 0.7×	608 1.0×	75	3.1k
Seiji Sakata Japan	18	1.2k 0.4×	1.1k 0.5×	766 0.5×	561 0.5×	529 0.9×	39	2.2k
Hidenori Haruta Japan	20	1.7k 0.5×	1.3k 0.5×	1.1k 0.7×	470 0.4×	286 0.5×	37	2.6k
David Fabrizio United States	26	1.0k 0.3×	1.9k 0.8×	666 0.4×	927 0.8×	504 0.8×	88	2.9k

Countries citing papers authored by Yuki Togashi

Since Specialization

Citations

This map shows the geographic impact of Yuki Togashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuki Togashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuki Togashi more than expected).

Fields of papers citing papers by Yuki Togashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuki Togashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuki Togashi. The network helps show where Yuki Togashi may publish in the future.

Co-authorship network of co-authors of Yuki Togashi

This figure shows the co-authorship network connecting the top 25 collaborators of Yuki Togashi. A scholar is included among the top collaborators of Yuki Togashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuki Togashi. Yuki Togashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kono, Yuta, et al.. (2025). Mini nutritional assessment short-form as a risk factor for mortality in patients with respiratory disease undergoing urgent hospitalization. BMC Geriatrics. 25(1). 113–113. 1 indexed citations

Sakata, Seiji, Satoko Baba, Yuki Togashi, et al.. (2024). Early gastric cancer with RhoGAP fusion is linked to frequent nodal metastasis and a part of microtubular–mucocellular histology. Gastric Cancer. 27(4). 772–784. 2 indexed citations

Urasaki, Tetsuya, Makiko Ono, Kyoko Yamashita, et al.. (2024). Confirmatory diagnosis and successive chemotherapeutic treatments of metastatic skeletal EWSR1::NFATC2 sarcoma: A case report. Oncology Letters. 29(3). 108–108.

Norimatsu, Yuta, Toshihisa Hamada, Ichiro Mori, et al.. (2023). Detection of TRAF1‐ALK fusion in skin lesions of systemic ALK+ anaplastic large cell lymphoma initially involving the skin and the draining lymph node. The Journal of Dermatology. 51(1). 120–124. 1 indexed citations

Kikuchi, Ryota, et al.. (2021). Impact of sarcopenia on chemotherapy‐triggered exacerbation of interstitial lung disease in patients with non‐small cell lung cancer. Thoracic Cancer. 13(4). 549–556. 10 indexed citations

Togashi, Yuki, et al.. (2020). Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID‐19. Respirology Case Reports. 8(9). e00679–e00679. 11 indexed citations

Yorita, Kenji, Yuki Togashi, Hideyuki Nakagawa, et al.. (2019). Vocal cord inflammatory myofibroblastic tumor with mucoid deposits harboring TIMP3–ALK fusion: A potential diagnostic pitfall. Pathology International. 69(6). 366–371. 7 indexed citations

Togashi, Yuki, Satoko Baba, Yo Kaku, et al.. (2018). Epithelioid cell histiocytoma with SQSTM1-ALK fusion: a case report. Diagnostic Pathology. 13(1). 28–28. 8 indexed citations

Togashi, Yuki, Akito Dobashi, Seiji Sakata, et al.. (2018). MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts. Modern Pathology. 31(6). 934–946. 64 indexed citations

10.

Kono, Yuta, Kenji Tsushima, Koichi Yamaguchi, et al.. (2013). The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis. Respiratory Medicine. 107(7). 1094–1100. 56 indexed citations

11.

Tsushima, Kenji, Shinya Sugiyama, Koichi Yamaguchi, et al.. (2012). Histological types and localizations of lung cancers in patients with combined pulmonary fibrosis and emphysema. Thoracic Cancer. 4(4). 354–360. 11 indexed citations

12.

Togashi, Yuki, Manabu Soda, Seiji Sakata, et al.. (2012). KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only. PLoS ONE. 7(2). e31323–e31323. 205 indexed citations

13.

Takeuchi, Kengo, Manabu Soda, Yuki Togashi, et al.. (2012). RET, ROS1 and ALK fusions in lung cancer. Nature Medicine. 18(3). 378–381. 963 indexed citations breakdown →

14.

Takeuchi, Kengo, Manabu Soda, Yuki Togashi, et al.. (2011). Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1–ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification. Clinical Cancer Research. 17(10). 3341–3348. 77 indexed citations

15.

Takeuchi, Kengo, Young Lim Choi, Yuki Togashi, et al.. (2009). KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer. Clinical Cancer Research. 15(9). 3143–3149. 557 indexed citations breakdown →

16.

Inamura, Kentaro, Kengo Takeuchi, Yuki Togashi, et al.. (2009). EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathology. 22(4). 508–515. 360 indexed citations

17.

Takeuchi, Kengo, Young Lim Choi, Manabu Soda, et al.. (2008). Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts. Clinical Cancer Research. 14(20). 6618–6624. 397 indexed citations

18.

Choi, Young Lim, Kengo Takeuchi, Manabu Soda, et al.. (2008). Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer. Cancer Research. 68(13). 4971–4976. 346 indexed citations

19.

Inamura, Kentaro, Kengo Takeuchi, Yuki Togashi, et al.. (2008). EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers. Journal of Thoracic Oncology. 3(1). 13–17. 374 indexed citations

20.

Inamura, Kentaro, Yuki Togashi, Michiyo Okui, et al.. (2007). HOXB2 as a Novel Prognostic Indicator for Stage I Lung Adenocarcinomas. Journal of Thoracic Oncology. 2(9). 802–807. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact